» Articles » PMID: 20207560

School Performance in a Cohort of Children with CNS Inflammatory Demyelination

Overview
Specialty Pediatrics
Date 2010 Mar 9
PMID 20207560
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Acute CNS inflammatory demyelination in childhood may induce permanent cognitive impairment. However, there has been no epidemiological assessment of prognostic factors for school performance in a cohort of children with such a disease.

Methods: The cohort consisted of 344 children from the French "KIDSEP" neuropediatric cohort with at least one clinically defined attack of CNS inflammatory demyelination occurring before the age of 16 years, and with at least two years of follow-up (inclusion from 1990 to 2003, follow-up until June 2007). We used multivariate survival analysis (Cox model) to evaluate the prognostic value for grade retention between the start of elementary school ( approximately 6 years of age) and the end of high school ( approximately 17-18 years of age), of variables related to both the socioeconomic status of the parents and the characteristics of the disease at onset.

Results: The cohort was monitored for a mean of 8.0+/-3.4 years. Grade retention after disease onset was recorded for 151 patients (43.9%). The risk of grade retention was significantly higher for boys, children from families with lower social status and poorer housing conditions, children over the age of 11 years at disease onset and children suffering optic neuritis or brainstem dysfunction at the first attack or irreversible disability, even if only moderate, following the first attack.

Conclusions: The risk factors for poor school performance are related to low socioeconomic status and to factors predictive of a relapsing severe course of the disease, leading to the diagnosis of multiple sclerosis.

Citing Articles

Effect of fingolimod on health-related quality of life in paediatric patients with multiple sclerosis: results from the phase 3 PARADIG Study.

Krupp L, Banwell B, Chitnis T, Deiva K, Gaertner J, Ghezzi A BMJ Neurol Open. 2022; 4(1):e000215.

PMID: 35308898 PMC: 8883212. DOI: 10.1136/bmjno-2021-000215.


Utilization and Treatment Patterns of Disease-Modifying Therapy in Pediatric Patients with Multiple Sclerosis in the United States.

Greenberg B, Kolodny S, Wang M, Deshpande C Int J MS Care. 2021; 23(3):101-105.

PMID: 34177381 PMC: 8218586. DOI: 10.7224/1537-2073.2019-095.


Enhancing Mood, Cognition, and Quality of Life in Pediatric Multiple Sclerosis.

Fernandez-Carbonell C, Charvet L, Krupp L Paediatr Drugs. 2021; 23(4):317-329.

PMID: 33997945 PMC: 8275506. DOI: 10.1007/s40272-021-00451-5.


Acquisition of Early Developmental Milestones and Need for Special Education Services in Pediatric Multiple Sclerosis.

Aaen G, Waltz M, Vargas W, Makhani N, Ness J, Harris Y J Child Neurol. 2018; 34(3):148-152.

PMID: 30556452 PMC: 6579723. DOI: 10.1177/0883073818815041.


Recommendations for cognitive screening and management in multiple sclerosis care.

Kalb R, Beier M, Benedict R, Charvet L, Costello K, Feinstein A Mult Scler. 2018; 24(13):1665-1680.

PMID: 30303036 PMC: 6238181. DOI: 10.1177/1352458518803785.